In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on how to personalize adjuvant therapy for these patients. Supported by an educational grant from Lilly.

Faculty:

Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Erin F. Cobain, MD
Associate Professor of Internal Medicine
Division of Hematology/Oncology
Breast Oncology Program
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Link to obtain CME/CE credit:
https://bit.ly/46RvtgH

Link to Oncology Breast Cancers with additional educational activities:
https://bit.ly/4h7R3AO

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer